SAM
KRYS icon

Smartleaf Asset Management’s Krystal Biotech KRYS Stock Holding History

Smartleaf Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Hold
308
– – ﹤0.01% 1094
2026
Q1 		$76.1K Sell
308
-302
-50% -$80.4K ﹤0.01% 1248
2025
Q4 		$151K Buy
610
+188
+45% +$39.6K 0.01% 955
2025
Q3 		$74.6K Buy
422
+212
+101% +$31.7K ﹤0.01% 1225
2025
Q2 		$29.2K Sell
210
-105
-33% -$15.4K ﹤0.01% 1399
2025
Q1 		$57.9K Buy
315
+177
+128% +$29.8K 0.01% 1076
2024
Q4 		$22.1K Buy
138
+54
+64% +$9.58K ﹤0.01% 1593
2024
Q3 		$14.9K Buy
84
+66
+367% +$12.7K ﹤0.01% 1520
2024
Q2 		$3.29K Buy
18
+14
+350% +$2.35K ﹤0.01% 2004
2024
Q1 		$708 Buy
+4
New +$556 ﹤0.01% 1689

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Smartleaf Asset Management's KRYS Position: Q2 2026 in Review

Smartleaf Asset Management held its Krystal Biotech (KRYS) position steady in Q2 2026 at 308 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #1094.

Smartleaf Asset Management first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. The position peaked at $151K in Q4 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Smartleaf Asset Management held 308 shares of Krystal Biotech worth $116K as of Q2 2026.
  • Smartleaf Asset Management left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1094 holding.
  • Smartleaf Asset Management first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
  • Smartleaf Asset Management's Krystal Biotech position peaked at $151K in Q4 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.